PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a one-time administered AAV gene therapy for Fabry disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE